Evolus (EOLS) Return on Capital Employed (2018 - 2026)
Evolus' (EOLS) quarterly Return on Capital Employed came in at 15.68% in Q1 2026, up 871.0% YoY from 1.61% in Q1 2025, and up 29.38% on a QoQ basis from 22.2% in Q4 2025.
Evolus (EOLS) Return on Capital Employed (2018 - 2026) Analysis & Trends
Evolus (EOLS) has 9 years of Return on Capital Employed data on file, last reported at 15.68% in Q1 2026.
- Quarterly Return on Capital Employed rose 871.0% year-over-year to 15.68% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 15.68% (up 871.0% YoY) and the FY2025 annual result came in at 21.22%, up 206.0% from the prior year.
- Return on Capital Employed climbed to 15.68% in Q1 2026, from 22.2% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 15.68% in Q1 2026 to a low of 48.3% in Q3 2022.
- A 5-year average of 32.83% and a median of 28.68% in 2024 frame the typical range for Return on Capital Employed.
- The widest YoY moves for Return on Capital Employed: up 9946 bps in 2022, down 2220 bps in 2022.
- Tracing EOLS's Return on Capital Employed over 5 years: stood at 47.05% in 2022, then grew by 20 bps to 37.82% in 2023, then jumped by 46 bps to 20.47% in 2024, then dropped by 8 bps to 22.2% in 2025, then gained by 29 bps to 15.68% in 2026.
- The last three Return on Capital Employed figures came in at 15.68% (Q1 2026), 22.2% (Q4 2025), and 24.94% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.02 Bn | 39.37 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.47 Bn | 29.79 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.59 Bn | 22.79 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.45 Bn | 15.06 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Evolus | 549.85 Mn | 504.68 Mn | 57.18 Mn | -13.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -13.77% |
| Mar 31, 2026 | -15.68% |
| Dec 31, 2025 | -22.20% |
| Sep 30, 2025 | -24.94% |
| Jun 30, 2025 | -27.44% |
| Mar 31, 2025 | -24.39% |
| Dec 31, 2024 | -20.47% |
| Sep 30, 2024 | -23.84% |
| Jun 30, 2024 | -22.01% |
| Mar 31, 2024 | -28.68% |
| Dec 31, 2023 | -37.82% |
| Sep 30, 2023 | -42.72% |
| Jun 30, 2023 | -45.18% |
| Mar 31, 2023 | -48.21% |
| Dec 31, 2022 | -47.05% |
| Sep 30, 2022 | -48.30% |
| Jun 30, 2022 | -45.01% |
| Mar 31, 2022 | -34.22% |
| Dec 31, 2021 | -24.85% |
| Sep 30, 2021 | -86.02% |